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Objectives: This study evaluated cost-effectiveness of posaconazole versus 
standard azole therapy (SAT; fluconazole or itraconazole) for prevention of inva-
sive fungal infection (IFI) in neutropenic patients from the Thai health care 
system perspective. MethOds: A decision-analytic model was developed based 
on data from clinical trials. The surviving patients in the decision tree were 
extrapolated to a lifetime horizon using Markov model in which mortality risk 
was specific to underlying disease. The rates of IFI, IFI-related mortality, overall 
mortality and treatment duration were obtained from published literature. The 
probability of IFI-related death of posaconazole was assumed to be equal to 
SAT for Scenario I (45%), and was lower than SAT for Scenario II (36% vs. 48%) as 
obtained from clinical trial. Data of IFI-related costs and health care resource 
utilization were obtained from local studies and expert opinion. Drug prices 
were those published by Ministry of Public Health. All costs were expressed in 
THB 2013 values. Future costs and outcomes were discounted at 3%. The model 
outcomes included costs, IFI avoided, life years saved (LYS) and incremental 
cost-effectiveness ratio (ICER) of posaconazole versus SAT. Results: In com-
parison with fluconazole/itraconazole, posaconazole was associated with fewer 
IFIs per patient (0.05 vs. 0.11) during 100-day follow-up. Over a lifetime horizon, 
prophylaxis with posaconazole resulted in lower discounted costs and a benefit 
of 0.06 and 0.07 in terms of discounted LYS for Scenario I and II, respectively. 
The probabilistic sensitivity analyses showed that there are 95.9% and 96.4% 
probabilities that posaconazole is cost-effective relative to fluconazole/itra-
conazole at the recommended threshold of 160,000 THB/LYS for such compari-
sons. cOnclusiOns: This analysis suggested that posaconazole is the dominant 
treatment strategy (more effective and less costly) for the prevention of IFI in 
patients with prolonged neutropenia in Thailand. Posaconazole prophylaxis may 
substantial diminish for the economic burden of IFI.
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Objectives: Dengue fever is a vector-borne disease prevalent in tropical and sub-
tropical regions. It is an important public health problem with a considerable and 
often under-valued disease burden in terms of frequency, cost and quality-of-life. 
Previous analyses have documented the cost-effectiveness of vaccination as well 
as a range of vector-control interventions. However, such analyses do not evaluate 
the cost-effectiveness of combined vaccination and vector control interventions. 
We seek to demonstrate the public health and economic value of interventions 
compared with the next best alternative embracing both vaccination as well as 
vector-control interventions. MethOds: Using a previously published dynamic 
compartmental model (Knerer 2013) able to consider dengue fever transmission, 
we assessed the impact of different vector-control, vaccination and mixed strate-
gies. We then combined the results with economic data to estimate the relative 
cost-effectiveness of dengue vector-control and vaccination strategies in different 
age-groups in Thailand. We estimated the expected costs and outcomes of indi-
viduals with dengue fever (vaccinated or not). Costs included direct medical costs 
such as the costs of vaccination, costs of hospitalisation, as well as the indirect 
costs of lost productivity. The health burden of dengue fever was assessed in rela-
tion to disability-adjusted life-years (DALYs) lost. Results: We found vaccination 
to be a cost-effective single intervention, both with imperfect efficacy (30.2%) 
as well as under more optimistic scenarios (70%). Cost-effectiveness ratios for 
vector-control strategies ranged from being cost-effective and even cost saving 
to cost ineffective with incremental cost-effectiveness ratios in excess of  WHO 
guidelines. In combination, control interventions and vaccination exhibited a 
marked impact on dengue fever transmission and proved to be a cost-effective 
strategy as well as delivering the potential for cost-savings. cOnclusiOns: By 
providing a high level of disease control, the implementation of a vaccination 
program in combination with vector-control strategies appears to be cost-effective 
and often cost-saving.
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Objectives: This study aims to assess the cost-effectiveness of hepatitis A vac-
cination in Indonesia, including an explicit comparison between one-dose and two-
dose vaccines. MethOds: An age-structured cohort model based on a decision 
tree was developed for the 2012 Indonesia birth cohort. Using the model, we made 
a comparison on the use of two-dose and one-dose vaccines. The model involves 
a 70-year time horizon with 1-month cycles for children less than 2 years old and 
annually thereafter. Monte Carlo simulations were used to examine the economic 
acceptability and affordability of the hepatitis A vaccination. Results: With the 
vaccine price of US$ 4.49 per dose, the implementation of the hepatitis A vaccine 
from the societal perspective would yield incremental-cost-effectiveness-ratios 
(ICERs) at US$ 9,194 and US$ 4,577 for the two-dose and one-dose vaccine sched-
ules, respectively. Considering the 2012 gross-domestic-product (GDP) per capita in 
Indonesia of US$ 3,557, the results indicate that hepatitis A vaccination would be 
a cost-effective intervention, both for the two-dose and one-dose vaccine sched-
ules. Vaccination would be 100% affordable at budgets of US$ 89,918,000 and US$ 
46,778,000 for the implementation of the two-dose and one-dose vaccine sched-
ules, respectively. cOnclusiOns: The implementation of hepatitis A vaccination 
in Indonesia would be a cost-effective health intervention under the market vaccine 
prices. Given the budget limitations, the use of a one-dose-vaccine schedule would 
be more realistic to be applied than a two-dose schedule. The discount rate, vac-
cine price, vaccine efficacy and mortality rate were the most influential parameters 
impacting the ICERs.
disease incidence and serotype coverage and health care utilization to compare 
costs and clinical impact of PCV-13 versus PCV-10 on IPD, inpatient and outpatient 
pneumonia, and AOM , among vaccinated children (direct effect) and the entire 
population with indirect(herd effects). Patients were entered in the model by age 
groups: ages 0-< 2 years, 2-4 years, 5-17 years, 18-34 years, 35-49 years, 50-64 years, 
65+ years. Only 0-2 year cohort was vaccinated. The local epidemiology and cost 
data were used to achieve national specificity. Direct/Indirect effectiveness of PCV-
13 and PCV-10 were calculated based on PCV-7 efficacy data, using assumptions 
regarding serotype coverage and PCV-10 and PCV-13 protection against additional 
serotypes. Results: In the analysis, PCV-13 vaccination has caused significant 
decline in all PD cases. It was estimated to prevent 19,918 cases of IPD, 3,796,657 
cases of pneumonia, and 53,310,807 cases of AOM in 10-year cohort. Also the incre-
mental cost per LYG was estimated at 10,043,048 won for the PCV-13 vaccination 
from the health care system perspective in the 10-year horizon, as compared to 
PCV-10 vaccination. cOnclusiOns: PCV-13 vaccination program provided eco-
nomic and clinical impact on overall PD prevention and cost-effective compared 
with PCV-10 vaccination.
PIN20
CosT-effeCTIveNess of maTerNal ImmuNIsaTIoN for PerTussIs IN New 
ZealaNd
Poirrier J.E.1, Mungall B.2, Lee I.H.3, Terlinden A.4, Curran D.1
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2GlaxoSmithKline, Auckland, New Zealand, 
3GlaxoSmithKline Vaccines, Singapore, 4Navigha, Tervuren, Belgium
Objectives: Despite routine vaccination, pertussis remains an important 
public health problem with an increase in annual incidences worldwide in 
recent years. Since infants too young to be protected by vaccination remain at 
risk of severe pertussis-related morbidity, New Zealand Authorities recommended 
and funded maternal immunisation against pertussis in 2013. In this study, we evalu-
ated the cost-effectiveness of adding a maternal immunisation program to routine 
vaccination prior to 2013 in New Zealand. MethOds: A decision-tree model was 
adapted from the literature. A cohort of infants below 1 year of age (corresponding 
to the birth cohort in New Zealand) and a cohort with their mothers are followed. 
Data on pertussis morbidity and costs were gathered for infants and their mothers. 
Health benefits (in quality-adjusted life-years [QALYs]) and costs were estimated. 
Incremental cost-effectiveness ratio was calculated from a payer’s perspective. The 
robustness of results was determined through scenario analysis (years of low, high 
and average incidence) and sensitivity analysis. Results: In the base-case analysis 
(average incidence 2009-2012, 20% coverage, 1:100 underreporting), maternal immuni-
sation was found to reduce the incidence of pertussis among infants (62 infant cases 
prevented) and was estimated to have a cost-effectiveness ratio of NZD 527.17/QALY 
from a payer’s perspective. During a high incidence year maternal immunisation 
was dominant. During a low incidence year maternal immunisation was estimated 
to have a cost-effectiveness ratio below NZD 32,577.42/QALY. In the scenario analysis, 
the cost-effectiveness of maternal immunisation remained below that ratio and even 
dominant in most cases. cOnclusiOns: This study estimated that the addition of 
maternal immunisation to the New Zealand national immunisation program was a 
cost-effective or even cost-saving decision. DISCLAIMER: This is a cost-effectiveness 
study only. There is currently no pertussis immunisation indication/label for preg-
nancy in New Zealand and any immunisation should be consistent with local product 
labelling.
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Objectives: Hepatitis C virus (HCV) is currently affecting more than 43 million 
persons in China, but the high cost of the standard drug therapy with pegylated 
interferon (PEG-IFN) inhibits many HCV infected patients to obtain appropriate treat-
ment. A newly developed domestic low-price PEG-IFN (Peginterferonalfα -2b (40kD, 
Y shape) is expected to benefit the patients greatly with an equally effective treat-
ment at substantially lower cost. This study provides the first scientific analysis to 
report the cost-effectiveness of this new drug treatment which is expected to be 
soon available for HCV infected patients in China. MethOds: Data was obtained 
from a multicenter, open and randomized, effective drug controlled phase 3 clinical 
trial. 242 eligible patients were randomized into the treatment group (PEG-IFNα -2b 
(40kD, Y shape) combined with RBV) and the control group (PEG-IFNα -2a combined 
with RBV). The effectiveness measure was sustained viral response (SVR). Costs, 
which were measured by direct medical costs, were obtained from medical records. 
An incremental cost-effectiveness ratio was calculated and probabilistic sensitivity 
analysis was conducted based on bootstrapping method. Results: The SVR rate of 
PEG-IFNα -2b(40kD, Y shape) cohort and PEG-IFNα -2a cohort were 85.44% and 79.52% 
(p= 0.2419) respectively. In the meantime, patients receiving PEG-IFNα -2b(40kD, Y 
shape) incurred significantly less costs compared to the PEG-IFNα -2a treated control 
group (CNY 29930.74 vs. 36743.90, P< 0.01). cOnclusiOns: Compared to PEG-IFNα -2a 
treatment, PEG-IFNα -2b (40kD, Y shape) treatment is equally effective at substantially 
lower costs. Sensitivity analysis conducted with bootstrapping method indicts a great 
possibility that PEG-IFNα -2b (40kD, Y shape) treatment is a cost-saving therapy.
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21-32 million and 418-456 QALY gained for 25% and 80% uptake. The results were 
sensitive to the proportion of inpatient presentation at ED and utility during influ-
enza. cOnclusiOns: Results clearly demonstrate that both 75 mg BID standard and 
150 mg BID high dose oseltamivir therapy are cost saving. The findings corroborate 
antiviral therapy as being a valuable component of pandemic influenza planning 
decisions in the US.
INfeCTIoN – Patient-reported outcomes & Patient Preference studies
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Objectives: To compare the efficacy of Xuebijing injection and ulinastatin injec-
tion for the treatment of inflammation and sepsis by evaluating plasma tumor 
necrosis factor (TNF-α ), interleukin IL-6, procalcitonin (PCT), the average length of 
stay and the average duration of mechanical ventilation. MethOds: Literatures 
from January 2004 to August 2013 were retrieved from the online databases such 
as CNKI, CQVIP and Wanfang Data. The documents and data, selected according to 
the inclusion and exclusion criteria, were analyzed by RevMan5.0 Meta-analysis 
software. Results: Four randomized controlled clinical trials were included, 
with 181 patients in the experimental group (Xuebijing +Ulinastatin +based treat-
ment) and 181 patients in the control group (Ulinastatin + basic treatment). Meta-
analysis showed that the tumor necrosis factor TNF-a levels [WMD = -5.16,95% CI 
(-11.07,0.76)] of experimental group and the control group were not statistically 
different, but the interleukin IL-6 levels[WMD= -57.82,95%CI (-112.12, -3.52)] , the 
procalcitonin PCT [WMD= -0.53,95%CI (-0.88, -0.19)] levels , the average length of 
stay [WMD = -3.63,95 % CI (-4.68, -2.58)] and the average duration of mechanical 
ventilation [WMD = -3.77,95% CI (-4.70, -2.83)] of the experimental group and the 
control group were statistically different. cOnclusiOns: Current results indicated 
that the application of Xuebijing injection for the treatment of sepsis provided a 
lower level of interleukin IL-6 and procalcitonin PCT, a shorter length of stay and 
duration of mechanical ventilation.
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Objectives: This study was conducted to evaluate the effect of a pharmacist ini-
tiated health education programme for improving Hepatitis-B patients’ disease 
state knowledge, attitude, practice and health related quality of life in Quetta city, 
Pakistan. MethOds: The study was conducted as non-clinical randomization control 
trial. It was divided into four phases: pre-interventional assessment, training of hospi-
tal pharmacists, development and implementation of the intervention program and 
post-interventional analysis. The pre-interventional phase analysed the Hepatitis-B 
(HB) patients’ knowledge, attitude and practice and current status of Health Related 
Quality of Life (HRQoL). Results: Three hundred and ninety HB patients were tar-
geted for the study. The pre-interventional analysis revealed poor knowledge (mean 
score 8.48 ±2.7 out of 20), negative attitude (mean scores 3.87±1.2 out of 7) and bad 
practice (mean scores 2.37±1.0 out of 8). The HB patients also had poor Health Related 
Quality of Life (mean score of 37.22±30.0 out of 100). The post-interventional data were 
available from 126 patients of interventional group and 151 patients of control group, 
giving a response rate of 64.6% and 77.4% respectively. No significant association was 
observed among demographics variables. However, knowledge, attitude and practice, 
and HRQoL scores were significantly associated (p< 0.001) when compared between 
interventional and control group after the completion of the intervention. There was 
an increase in mean knowledge score (15.46±2.2), attitude score (5.05±1.1), practice 
(5.98±1.1) Health Related Quality of Life (48.16±25.2). The inter-group difference among 
pre- and post- interventional groups reported a significant difference (p< 0.001) when 
knowledge, attitude and practice and HRQoL were compared. cOnclusiOns: The 
educational intervention significantly increase in the HB patients’ knowledge, attitude 
and practice, and HRQoL. Therefore, the role of pharmacists in patient education 
must be formalized and acknowledged as an official part of the health care system.
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Objectives: The main aims of the study was to estimate the health related qual-
ity of life(HRQOL) between Adverse drug reaction (ADR) and Non ADR retroviral 
patients who are on anti retroviral therapy. MethOds: A prospective spontaneous 
, reporting study was conducted over a period of 6 months by clinical pharmacist. 
Each reported ADR was assessed for its causality and severity by using Naranjo ‘s 
scale and Hartwig et al scale .The management of reported ADRs and the treatment 
given for ADR are determined. Health related quality of life is assessed by giving a 
35 item MOS- HIV Questionnare to each individual retroviral patients who are on 
Highly active antiretroviral therapy (HAART) for atleast 45 days by calculating the 
HRQOL score. Results: A Total of 46 ADRs (N= 100) were identified out of which 
30 are males and 16 are females. The assessment by Naranjos scale showed that 
out of 46 ADRs, 8 ADRs were probable, 35 ADRs were possible and 3 ADRs were 
unlikely. Severity assessment by hartwig et al scale showed that 32 ADRs come 
under mild level, 14 ADRs come under moderate level and none come under severe 
level.The Health related quality of life between ADR patients and Non ADR absent 
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Objectives: Breast milk is considered to give protection against rotavirus infection 
since it contains anti-rotavirus maternal antibodies and other nonspecific inhibi-
tors. Multilevel promotion of breastfeeding is a complex intervention that modifies 
behavioral determinants through multiple levels of health promotion. This interven-
tion can prolong the duration and increase the prevalence of exclusive breastfeed-
ing. This study aims to investigate the effect of multilevel promotion of breastfeeding 
on reducing the required budget for rotavirus vaccination in Indonesia. MethOds: 
We developed an age-structured cohort model within a 5-year-time-horizon for the 
2013 Indonesia birth cohort. We compared two situations: (i) baseline, reflecting 
the current situation for the population of under-5-years-old, and (ii) the current 
situation with an additional multilevel promotion of breastfeeding. We used Monte 
Carlo simulations to examine the economic acceptability and affordability of the 
rotavirus vaccination. Results: Vaccination coupled with multilevel promotion 
of breastfeeding could reduce rotavirus-diarrhea by 493,235 cases. At a vaccine 
price of US$ 5.0 per dose, multilevel promotion of breastfeeding could reduce the 
required budget for the implementation of three-dose rotavirus vaccination by US$ 
50,000, compared to the current absence of specific promotion. cOnclusiOns: 
Multilevel promotion of breastfeeding could potentially reduce the required budget 
for rotavirus vaccination. Mortality rate and vaccine price were the most influential 
parameters on the sensitivity analyses.
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Objectives: The objective of this study is to evaluate the costs-effectiveness of 
introducing pneumococcal conjugate vaccine as part of the childhood immuniza-
tion program in the Philippines. MethOds: A cost-utility analysis was conducted 
using a lifetime horizon. A Markov simulation model was used to examine the 
comparative cost-effectiveness of PCV10 and PCV13 against the current scenario 
of no vaccination. A health system perspective was employed to explore different 
funding schemes, which include full or partial vaccination coverage subsidized by 
the government and self-paid vaccination in the private sector. An annual discount 
rate of 3.5% for future costs and outcomes was applied. Results were presented as 
incremental cost-effectiveness ratios (ICERs) per QALY gained. Sensitivity analysis 
was performed to determine the impact of parameter uncertainty. Results: With 
universal vaccination by the government at a cost per dose of Php 624 for PCV10 and 
Php700 for PCV13, the ICER for PCV10 and PCV13 were Php 68,086 and Php 67,631 
per QALY gained, respectively, compared to no vaccination. Partial vaccination of 
25% and 50% of the birth cohort yielded considerably higher ICER values that are 
still below the country ceiling threshold of Php 170,000 per QALY gained, because of 
the loss of herd protection. The analysis also found that with a partial vaccination 
strategy of the government, having at least 10% of the target cohort self-pay a higher 
market price of Php 2.056 for PCV10 and Php 3,545 for PCV13 would make vaccina-
tion cost-ineffective, because of the high out-of-pocket costs. cOnclusiOns: The 
inclusion of PCV in the national immunization program with either universal or 
partial coverage would be a cost-effective intervention in the Philippines compared 
to no vaccination. However, the affordability and sustainability of PCV implementa-
tion over the long term should be considered by decision makers.
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Objectives: Some recent pharmacological evaluations support that higher expo-
sures of oseltamivir may further reduce duration of influenza viral shedding and 
symptoms. This study investigated the economic impact of oseltamivir standard 
(75 mg BID) and high (150 mg BID) dose treatment and its potential in supporting 
pandemic influenza planning decisions in the US. MethOds: A health economic 
(HE) decision analytic model was linked to a pharmacokinetic/pharmacodynamics 
(PK/PD) - transmission dynamic model which simulated the infected population 
in an influenza outbreak under different scenarios. A cost-utility analysis, under 
the US societal perspective, was conducted; comparing oseltamivir 150mg versus 
approved 75mg BID, and no treatment, three levels of uptake (25%, 50%, and 80%), for 
a strain with comparable virulence to typical seasonal-influenza. Model parameters 
such as probabilities, costs (2013 USD), lengths of stay, and utilities were derived 
from published studies. In the HE model, an infected patient was either treated 
with oseltamivir in the outpatient setting or admitted into the hospital, leading 
to no complications, pneumonia, sepsis, and acute respiratory distress syndrome. 
Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness 
ratios (ICERs) were determined over one-year time horizon. Sensitivity analyses 
were undertaken. Results: Under low virulence and low transmissibility scenarios, 
in comparison with no treatment, the use of 75mg BID oseltamivir showed cost-
saving of USD 31-33 million million and 395-452 QALY gained for 25% and 80% 
uptake, respectively. Compared to no treatment, oseltamivir 150 mg BID saved USD 
